Charles River Laboratories | CRL - Selling And Administration Expenses

Stock Price
150.85
Daily Change
-8.27 -5.20%
Monthly
-14.75%
Yearly
7.01%
Q2 Forecast
173.94

Charles River Laboratories reported $159.42M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agilent USD 476M 48M Dec/2025
Align Technology USD 465.34M 23.67M Mar/2026
Bio-Rad Laboratories USD 221M 14.2M Dec/2025
Bruker USD 242.1M 5.1M Mar/2026
Cardinal Health USD 1.51B 6M Mar/2026
Charles River Laboratories USD 159.42M 36.71M Mar/2026
Cigna USD 3.32B 291M Mar/2026
Concord Medical Services Hldg CNY 140.37M 36.24M Jun/2025
Danaher USD 1.86B 166M Mar/2026
Dentsply International USD 351M 32M Mar/2026
Elevance Health USD 10.91B 309M Dec/2025
Humana USD 3.36B 614M Mar/2025
Illumina USD 272M 11M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
IQVIA Holdings USD 502M 34M Mar/2026
Laboratory Of America USD 551M 12.4M Mar/2026
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
McKesson USD 1.8B 234M Mar/2026
Merck EUR 1.6B 136M Dec/2025
Mettler Toledo International USD 258.33M 1.5M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Quest Diagnostics USD 504M 0 Mar/2026
Revvity USD 253.88M 2.15M Mar/2026
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
UnitedHealth USD 15.22B 1.44B Sep/2025
Veradigm USD 27.28M 5.24M Dec/2022
Waters USD 394M 153.99M Mar/2026
West Pharmaceutical Services USD 99.5M 7M Mar/2026